

L Number	Hits	Search Text	DB	Time stamp
4	59	(ekwuribe-nnochiri\$ or price-christopher\$ or ansari-aslam\$ or odenbaugh\$).in.	USPAT; US-PGPUB	2004/01/31 13:07

Checked L4

JZ

1-31-2004

Day : Saturday  
Date: 1/31/2004

Time: 12:57:50

PALM INTRANET

## Inventor Information for 09/873797

Inventor Name	City	State/Country
EKWURIBE, NNOCHIRI N.	CARY	NORTH CAROLINA
PRICE, CHRISTOPHER H.	CHAPEL HILL	NORTH CAROLINA
ANSARI, ASLAM M.	ROCKVILLE	MARYLAND
ODENBAUGH, AMY L.	MORRISVILLE	NORTH CAROLINA

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity Data](#)[Foreign Data](#)Search Another: Application# or Patent#  PCT /  /  or PG PUBS # Attorney Docket #  Bar Code #  

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Checked  
Jen  
1-31-2004

L Number	Hits	Search Text	DB	Time stamp
9	93	(conjugat\$ same ((peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$))) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:41
10	223	(conjugat\$ or peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and (514/2,11,12,21; 530/345,410; 528/425; 554/227; 562/587; 568/613,618,622,623).ccls. and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:15
11	204	((conjugat\$ or peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and (514/2,11,12,21; 530/345,410; 528/425; 554/227; 562/587; 568/613,618,622,623).ccls. and @pd>20030204) not ((conjugat\$ same ((peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$))) and @pd>20030204)	USPAT; US-PGPUB	2004/01/31 15:20
12	1	2000wo-jp09159.ap.	USPAT; US-PGPUB; DERWENT	2004/01/31 15:30
13	187	(polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:42
14	36	(polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$) with (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:35
15	42	(polyalkyleneglycol or polyalkylene adj glycol or polyoxyalkylene\$ or oxyalkylene\$) with (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:42
16	1053	(424/193.1-197.11).ccls.	USPAT; US-PGPUB	2004/01/31 15:41
17	3991	conjugat\$ with (peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$ or polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$ or polyalkyleneglycol or polyalkylene adj glycol or polyoxyalkylene\$ or oxyalkylene\$)	USPAT; US-PGPUB	2004/01/31 15:43
18	62	((424/193.1-197.11).ccls.) and (conjugat\$ with (peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$ or polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$ or polyalkyleneglycol or polyalkylene adj glycol or polyoxyalkylene\$ or oxyalkylene\$))	USPAT; US-PGPUB	2004/01/31 15:43

Checked L9, L10, L11, L14, L15, L18  
JSL 1-31-2004

DERWENT-ACC-NO: 1992-367710

DERWENT-WEEK: 199911

COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Hypocalcaemic calcitonin conjugates  
- comprise carboxylic acid gp. bonded to polymer  
having polyethylene glycol derivs.

INVENTOR: BAUDRIHAYE, M; DE CLERCQ, P ; MATHIEU, F ;  
WANTIER, H

PATENT-ASSIGNEE: TEVA PHARM IND LTD[TEVAN] , MEDGENIX  
GROUP SA[MEDGN]

PRIORITY-DATA: 1991FR-0004990 (April 23, 1991)

PATENT-FAMILY:

PUB-NO	PAGES	PUB-DATE	
LANGUAGE		MAIN-IPC	
EP 511903 A2		November 4, 1992	F
009	C08G	065/32	
ES 2124247 T3		February 1, 1999	N/A
000	C08G	065/32	
FR 2675807 A1		October 30, 1992	N/A
020	C08G	065/32	
EP 511903 A3		August 11, 1993	N/A
000	C08G	065/32	
EP 511903 B1		October 14, 1998	F
000	C08G	065/32	
DE 69227276 E		November 19, 1998	N/A
000	C08G	065/32	

DESIGNATED-STATES: AT BE CH DE DK ES FR GB GR IT LI LU MC  
NL PT SE AT BE CH DE  
DK ES FR GB GR IT LI LU MC NL PT SE

CITED-DOCUMENTS: No-SR.Pub; 1.Jnl.Ref ; EP 400472 ; EP  
400486 ; JP 61178926  
; US 4179337

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-DESCRIPTOR	APPL-NO
EP 511903A2		N/A	
1992EP-0401164		April 23, 1992	
ES 2124247T3		N/A	
1992EP-0401164		April 23, 1992	
ES 2124247T3		Based on	EP 511903
N/A			
FR 2675807A1		N/A	
1991FR-0004990		April 23, 1991	
EP 511903B1		N/A	
1992EP-0401164		April 23, 1992	
DE 69227276E		N/A	
1992DE-0627276		April 23, 1992	
DE 69227276E		N/A	
1992EP-0401164		April 23, 1992	
DE 69227276E		Based on	EP 511903
N/A			

INT-CL (IPC): A61K047/48, C07K007/36 , C07K017/08 ,  
C08G065/32

ABSTRACTED-PUB-NO: EP 511903A

#### BASIC-ABSTRACT:

Calcitonin conjugates (I) comprise a calcitonin (II) covalently bonded via at least one COOH gp. to at least one polymer (III) having a polyethylene glycol (PEG) chain.

USE/ADVANTAGE - Used in the treatment of osteoporosis, hypercalcaemia, Paget's disease, acute pancreatitis and sudeckatrophy. (I) have a longer plasma half-life, are less immunogenic, have almost the same receptor binding affinity, and have comparable hypocalcaemic activity in vivo. Pref. (III) is a PEG deriv. of formula  $\text{Me}(\text{OCH}_2\text{CH}_2)_n\text{NH}_2$ , where N is molecular wt. of 500-20,000, esp. 400-10,000. (III) is human, salmon or eel calcitonin or a calcitonin analogue with Asp or Glu in posn. 15. (II) is coupled to (III) through a peptide bond linking the COOH gp. in position 15

with the NH<sub>2</sub> gp. in  
(II).

ABSTRACTED-PUB-NO: EP 511903B

EQUIVALENT-ABSTRACTS:

Calcitonin conjugates (I) comprise a calcitonin (II) covalently bonded via at least one COOH gp. to at least one polymer (III) having a polyethylene glycol (PEG) chain.

USE/ADVANTAGE - Used in the treatment of osteoporosis, hypercalcaemia, Paget's disease, acute pancreatitis and sudeckatrophy. (I) have a longer plasma half-life, are less immunogenic, have almost the same receptor binding affinity, and have comparable hypocalcaemic activity in vivo. Pref. (III) is a PEG deriv. of formula Me(OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, where N is molecular wt. of 500-20,000, esp. 400-10,000. (III) is human, salmon or eel calcitonin or a calcitonin analogue with Asp or Glu in posn. 15. (II) is coupled to (III) through a peptide bond linking the COOH gp. in position 15 with the NH<sub>2</sub> gp. in (II).

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: HYPOCALCAEMIC CALCITONIN CONJUGATE COMPRISE  
CARBOXYLIC ACID GROUP  
BOND POLYMER POLYETHYLENE GLYCOL DERIVATIVE

DERWENT-CLASS: A96 B04

CPI-CODES: A10-E07; A12-V01; B04-B02D3; B04-C03C; B12-G01;  
B12-G03; B12-G07;  
B12-J08;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

D011 D601 F012 F014 F423 F521 G010 G013 G100 H1  
H100 H101 H181 H182 H4 H401 H402 H441 H481 H482

H5 H589 H598 H8 H9 J0 J011 J012 J1 J111  
J171 J172 J211 J271 J3 J311 J371 K0 K2 K224  
L2 L250 M210 M211 M271 M280 M281 M311 M312 M313  
M314 M315 M320 M321 M323 M331 M332 M333 M340 M342  
M343 M349 M371 M381 M383 M391 M393 M423 M510 M511  
M520 M521 M530 M531 M540 M620 M710 M903 M904 P420  
P610 P714 Q233 V0 V743 V901 V902 V917 V922  
Markush Compounds  
199245-09501-N  
Registry Numbers  
92407

UNLINKED-DERWENT-REGISTRY-NUMBERS: 1874S; 2044S

POLYMER-MULTIPUNCH-CODES-AND-KEY-SERIALS:

Key Serials: 0013 0231 1279 1588 2000 2002 2014 2180 2197  
2198 2400 2585 2675  
2766

Multipunch Codes: 014 028 04- 147 198 231 24& 240 31- 336  
359 402 420 525 575  
583 589 62- 645 688 720

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1992-163295